GT Biopharma, Inc. (GTBP) stock
Close on Nov 13, 2026Market cap $167.81MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $167.81M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 29.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$4.76M
- EPS, diluted
- -$6.68
- Book value per share
- $0.09
- Diluted shares
- 39M
Trading
- Previous close
- $3.84
- Open
- $3.85
- Day's range
- $3.60 – $4.11
- Volume
- 66,917
- Average volume (20 days)
- 75,343
- Beta (5 years)
- 0.82
- 52-week range
- $3.60 – $28.75
- RSI (14 days)
- 29.9
- Volatility (1 year)
- 125.1%
- Relative volume
- 1.13×
- WACC
- 9.2%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | GTBP | S&P 500 | Difference | GTBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -42.8% | -3.0% | −39.7 pts | ||
| 3 months | -50.0% | -2.8% | −47.2 pts | ||
| Year to date | -81.0% | +11.5% | −92.5 pts | ||
| 1 year | -79.6% | +13.5% | −93.1 pts | ||
| 3 years | -97.8% | +77.7% | −175.5 pts | -72.2% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.5 pts | -75.1% | +11.5% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases GT Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- Update
- News
About GT Biopharma
Pharmaceutical Preparations
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology products. Its therapies utilize proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein platforms. These therapeutics harness and enhance the cancer-killing capabilities of a patient's own natural killer cells to target hematologic malignancies, solid tumors, and viral infections. The company's candidate pipeline includes GTB-3550 and next-generation candidates such as GTB-3650, which target specific tumor antigens like CD33. Its therapeutics are intended for cancer patients as monotherapies or in combination with standard care.
Company profile, executives and historyGT Biopharma stock: common questions
What is GT Biopharma's stock price?
GTBP closed at $3.72 on Nov 13, 2026, down 3.12% on the day. Over the past 52 weeks it traded between $3.60 and $28.75.
What is GT Biopharma's market cap?
GT Biopharma was worth $167.81M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is GTBP's P/E ratio?
GT Biopharma lost money over fiscal 2025 (diluted EPS -$6.68), so it has no meaningful P/E ratio.
Does GT Biopharma pay a dividend?
No. GT Biopharma has not paid a cash dividend over the last twelve months.
How has GTBP stock performed over the past year?
Including dividends, GTBP returned -79.6% over the past year, against +13.5% for the S&P 500.
How many GTBP shares are sold short?
0M shares were sold short at the latest FINRA report, 0.56% of the float, or 3.2 days of average trading volume.
Who are GT Biopharma's competitors?
Companies most similar to GT Biopharma by business, industry and size include BOLT, NKTR, APVO, HURA, XLO.
See a number that looks wrong?